Oct 11, 2016 | Inside, Research
After being inserted into a patient’s upper arm, this implantable device delivers low-level doses of buprenorphine for six months.
The U.S. Food and Drug Administration, following a nationwide clinical study by researchers at the Mount Sinai Health System, recently approved the first implantable form of buprenorphine—a drug used to treat opioid addiction. The implant, called Probuphine, delivers low-level doses of the medication for six months after being inserted under the skin on the inside of a patient’s upper arm. (more…)
Oct 11, 2016 | Inside, Research
Adriana Feder, MD, center, with Leah Cahn, LMSW, Clinical Social Worker, left, and Olivia Diab, Clinical Research Coordinator.
Fifteen years after the destruction of the World Trade Center, many first responders continue to grapple with health issues stemming from their work at Ground Zero, including those who report symptoms of posttraumatic stress disorder (PTSD).
In a recently published study in the Journal of Psychiatric Research, researchers led by Adriana Feder, MD, Associate Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai, found that police responders, who had more training and preparedness for disaster response, continued to maintain lower rates of elevated PTSD symptoms than construction workers or other “nontraditional” responders. Dr. Feder also serves as Associate Director for Research at the World Trade Center Mental Health Program at Mount Sinai. (more…)
Oct 6, 2016 | Inside, Research, School
The agreement was signed by, from left: Kenneth L. Davis, MD, President and Chief Executive Officer, Mount Sinai Health System; Kenneth Kaushansky, MD, Dean of the Stony Brook University School of Medicine; and Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, and President for Academic Affairs, Mount Sinai Health System.
The Icahn School of Medicine at Mount Sinai and the Stony Brook University School of Medicine have entered into an affiliation agreement that will build on a shared “culture of innovation” to enrich academic medicine programs and pursue breakthroughs in treating and understanding disease.
“Mount Sinai and Stony Brook bring unique strengths to this partnership,” says Kenneth L. Davis, MD, President and Chief Executive Officer of the Mount Sinai Health System. “Together we are committed to finding new ways to enhance academics and clinical care.” (more…)
Sep 15, 2016 | Inside, Research
A novel method for characterizing prostate cancer that uses computer vision and artificial intelligence to help determine the best course of treatment for each patient is being rolled out this summer by the Lillian and Henry M. Stratton-Hans Popper Department of Pathology at the Icahn School of Medicine at Mount Sinai.
The platform, called Precise Medical Diagnosis™ or Precise MD, has been under development at Mount Sinai for more than three years by a team of physicians, scientists, mathematicians, engineers, and programmers. The proprietary diagnostic system creates detailed, specific data about the patient’s cancer cells using multispectral fluorescent imaging to evaluate biomarker status and architectural patterns and then uses sophisticated computer analytics to combine and create predictive models. (more…)
Sep 15, 2016 | Inside, Research
Researchers at the Icahn School of Medicine at Mount Sinai are pioneering the use of a new imaging agent used with positron emission tomography (PET) to detect and track the progression of repetitive traumatic brain injury in patients with a history of concussions.
The ability to actually see chronic traumatic encephalopathy (CTE) in living patients is particularly significant because the neurodegenerative disorder—associated with repetitive traumatic brain injury in athletes and soldiers—can only be definitively diagnosed in brain tissue after they are deceased. (more…)
Sep 9, 2016 | Research, School
On September 25-28 2016, the Division of Occupation and Environmental Medicine at the Icahn School of Medicine at Mount Sinai will host MANGANESE2016, an international conference on the neurotoxicity and prevention of adverse manganese health effects.
Manganese is a metal used in the production of steel and other metal manufacturing. Industrial use of manganese sometimes releases high concentrations of it in the air via dust or fumes, making workers in these industries and residents of these areas especially susceptible to manganese-related health conditions. (more…)
